Abstract
In the last two decades, the development of Positron Emission Tomography (PET), and then PET with Computed Tomography (PET/CT) imaging, has had a large impact on the management of a number of cancer types. PET/CT imaging benefits from the possibility of obtaining both structural (CT) and functional (PET) cancer information at the same time. PET obtains images of the biodistribution of radiopharmaceuticals that can be designed to target different biological processes. In current clinical cancer imaging, most PET imaging studies are performed using an analog of glucose, fluorodeoxyglucose (FDG), labeled with the radioactive Fluorine-18. Imaging with FDG is particularly useful because following malignant transformation, various tumors are characterized by increased glucose utilization that is reflected by increased uptake and accumulation of FDG. In oncology, PET imaging with FDG often provides more sensitive and more specific information about the extent of disease than morphologic/anatomic imaging alone. PET also offers an earlier and often better assessment of response to treatment and an overall better accuracy to restage disease after completion of a treatment course. This in turns results in an overall improved prognostic evaluation during and after treatment. Although the role of PET/CT is limited in patients with HCC, the current status of this imaging technology is reviewed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Brown RS, Wahl RL (1993) Overexpression of glut-1glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72(10):2979–85
Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231(2):305–32
Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508
Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s Lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752
Hillner BE, Siegel BA, Liu D et al (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26:2155–216
Podoloff DA, Ball DW, Ben-Josef et al (2010) NCCN Task Force Report: clinical utility of PET in a variety of tumor types. J Natl Compr Cancer Netw 7(Suppl 2)
Wiering B, Krabbe PF, Jager GJ et al (2005) The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104:2658–2670
Blue Cross Blue Shield Association(2000) FDG positron emission tomography in colorectal CA. Technology Evaluation Center (TEC) Assessments. Vol. 14
Delbeke D, Martin WH, Sandler MP et al (1998) Evaluation of benign vs. malignant hepatic lesions with positron emission tomography. Arch Surg 133:510–516
Wudel LJ, Delbeke D, Morris D et al (2003) The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 69:117–126
Lee JW, Paeng JC, Kang KW et al (2009) Prediction of tumor response by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682–687
Higashi E, Hatano E, Ikai I et al (2010) FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 37:468–482
Langenhoff BS, Oyen WJG, Jager GJ et al (2002) Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 20:4453–4458
Donckier V, Van Laethem JL, Goldman S et al (2003) [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 84:215–223
Kim Ho, Kim JS, Shin YM et al (2010) Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med 51:1849–1856
Szyszko T, Nahhas AA, Canelo R et al (2007) Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun 28:15–20
Popperl G, Helmberger T, Munzing W et al (2005) Selective internal radiation therapy with SIR-spheres in patients with nonresectable liver tumours. Cancer Biother Radiopharm 20:200–208
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Esposito, G. (2015). Imaging in Hepatocellular Carcinoma: PET/CT. In: Berliner, L., Lemke, H. (eds) An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Advances in Predictive, Preventive and Personalised Medicine, vol 8. Springer, Cham. https://doi.org/10.1007/978-3-319-12166-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-12166-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12165-9
Online ISBN: 978-3-319-12166-6
eBook Packages: MedicineMedicine (R0)